Anthony H. Cincotta

Dr. Anthony H. Cincotta

orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2012 in Journal of the American Heart Association
Verified
Journal Article
Open access
JGJ. Michael Gaziano
J. Michael Gaziano
ACAnthony H. Cincotta
Anthony H. Cincotta
AVAaron Vinik
Aaron Vinik
LBLawrence Blonde
Lawrence Blonde
NBNancy Bohannon
Nancy Bohannon
RSRichard Scranton
Richard Scranton
Background: Bromocriptine‐ QR (a quick‐release formulation of bromocriptine mesylate), a dopamine D2 receptor agonist, is a US F ood and D rug A dministrration–approved treatment for type 2 diabetes mellitus ( T2DM ). A 3070‐subject randomized trial demonstrated a significant, 40% reduction in relative risk among bromocriptine‐ QR ‐treated subjects in a prespecified composite cardiovascular ( CV ) end point that included ischemic‐related (myocardial infarction and stroke) and nonischemic‐related (hospitalization for unstable angina, congestive heart failure [ CHF ], or revascularization surgery) end points, but did not include cardiovascular death as a component of this composite. The present investigation was undertaken to more critically evaluate the impact of bromocriptine‐ QR on cardiovascular outcomes in this study subject population by (1) including CV death in the above‐described original composite analysis and then stratifying this new analysis on the basis of multiple demographic subgroups and (2) analyzing the influence of this intervention on only the “hard” CV end points of myocardial infarction, stroke, and CV death (major adverse cardiovascular events [ MACE s]). Methods and Results: Three thousand seventy T2DM subjects on stable doses of ≤2 antidiabetes medications (including insulin) with HbA1c ≤10.0 (average baseline HbA1c =7.0) were randomized 2:1 to bromocriptine‐ QR (1.6 to 4.8 mg/day) or placebo for a 52‐week treatment period. Subjects with heart failure ( N ew Y ork H eart C lasses I and II) and precedent myocardial infarction or revascularization surgery were allowed to participate in the trial. Study outcomes included time to first event for each of the 2 CV composite end points described above. The relative risk comparing bromocriptine‐ QR with the control for the cardiovascular outcomes was estimated as a hazard ratio with 95% confidence interval on the basis of C ox proportional hazards regression. The statistical significance of any between‐group difference in the cumulative percentage of CV events over time (derived from a K aplan– M eier curve) was determined by a log‐rank test on the intention‐to‐treat population. Study subjects were in reasonable metabolic control, with an average baseline HbA1c of 7.0±1.1, blood pressure of 128/76±14/9, and total and LDL cholesterol of 179±42 and 98±32, respectively, with 88%, 77%, and 69% of subjects being treated with antidiabetic, antihypertensive, and antihyperlipidemic agents, respectively. Ninety‐one percent of the expected person‐year outcome ascertainment was obtained in this study. Respecting the CV ‐inclusive composite cardiovascular end point, there were 39 events (1.9%) among 2054 bromocriptine‐ QR ‐treated subjects versus 33 events (3.2%) among 1016 placebo subjects, yielding a significant, 39% reduction in relative risk in this end point with bromocriptine‐ QR exposure ( P =0.0346; log‐rank test) that was not influenced by age, sex, race, body mass index, duration of diabetes, or preexisting cardiovascular disease. In addition, regarding the MACE end point, there were 14 events (0.7%) among 2054 bromocriptine‐ QR ‐treated subjects and 15 events (1.5%) among 1016 placebo‐treated subjects, yielding a significant, 52% reduction in relative risk in this end point with bromocriptine‐ QR exposure ( P <0.05; log‐rank test). Conclusions: These findings reaffirm and extend the original observation of relative risk reduction in cardiovascular adverse events among type 2 diabetes subjects treated with bromocriptine‐ QR and suggest that further investigation into this impact of bromocriptine‐ QR is warranted. Clinical Trial Registration: URL: http://clinicaltrials.gov . Unique Identifier: NCT00377676

25 June 2007 in BMC Endocrine Disorders
Verified
Journal Article
Open access
PDF file
RSRichard E Scranton
Richard E Scranton
JGJ Michael Gaziano
J Michael Gaziano
DRDean Rutty
Dean Rutty
MEMichael Ezrokhi
Michael Ezrokhi
ACAnthony H. Cincotta
Anthony H. Cincotta
Cycloset™ is a quick-release formulation of bromocriptine mesylate, a dopamine agonist, which in animal models of insulin resistance and type 2 diabetes acts centrally to reduce resistance to insulin- mediated suppression of hepatic glucose output and tissue glucose disposal. In such animals, bromocriptine also reduces hepatic triglyceride synthesis and free fatty acid mobilization, manifesting decreases in both plasma triglycerides and free fatty acids. In clinical trials, morning administration of Cycloset™ either as monotherapy or adjunctive therapy to sulfonylurea or insulin reduces HbA1c levels relative to placebo by 0.55–1.2. Cycloset™ therapy also reduces plasma triglycerides and free fatty acid by approximately 25% and 20%, respectively, among those also receiving sulfonylurea therapies. The effects of once-daily morning Cycloset™ therapy on glycemic control and plasma lipids are demonstrable throughout the diurnal portion of the day (7 a.m. to 7 p.m.) across postprandial time points.

25 September 2014 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
MEMichael Ezrokhi
Michael Ezrokhi
SLShuqin Luo
Shuqin Luo
YTYelena Trubitsyna
Yelena Trubitsyna
ACAnthony H. Cincotta
Anthony H. Cincotta
The hypertensive, pro-inflammatory, obese state is strongly coupled to peripheral and hepatic insulin resistance (in composite termed metabolic syndrome [MS]). Hepatic pro-inflammatory pathways have been demonstrated to initiate or exacerbate hepatic insulin resistance and contribute to fatty liver, a correlate of MS. Previous studies in seasonally obese animals have implicated an important role for circadian phase-dependent increases in hypothalamic dopaminergic tone in the maintenance of the lean, insulin sensitive condition. However, mechanisms driving this dopaminergic effect have not been fully delineated and the impact of such dopaminergic function upon the above mentioned parameters of MS, particularly upon key intra-hepatic regulators of liver inflammation and lipid and glucose metabolism have never been investigated. This study therefore investigated the effects of timed daily administration of bromocriptine, a potent dopamine D2 receptor agonist, on a) ventromedial hypothalamic catecholamine activity, b) MS and c) hepatic protein levels of key regulators of liver inflammation and glucose and lipid metabolism in a non-seasonal model of MS - the hypertensive, obese SHR rat. Sixteen week old SHR rats maintained on 14 hour daily photoperiods were treated daily for 16 days with bromocriptine (10 mg/kg, i.p.) or vehicle at 1 hour before light offset and, subsequent to blood pressure recordings on day 14, were then utilized for in vivo microdialysis of ventromedial hypothalamic catecholamine activity or sacrificed for the analyses of MS factors and regulators of hepatic metabolism. Normal Wistar rats served as wild-type controls for hypothalamic activity, body fat levels, and insulin sensitivity. Bromocriptine treatment significantly reduced ventromedial hypothalamic norepinephrine and serotonin levels to the normal range and systolic and diastolic blood pressures, retroperitoneal body fat level, plasma insulin and glucose levels and HOMA-IR relative to vehicle treated SHR controls. Such treatment also reduced plasma levels of C-reactive protein, leptin, and norepinephrine and increased that of plasma adiponectin significantly relative to SHR controls. Finally, bromocriptine treatment significantly reduced hepatic levels of several pro-inflammatory pathway proteins and of the master transcriptional activators of lipogenesis, gluconeogenesis, and free fatty acid oxidation versus control SHR rats. These findings indicate that in SHR rats, timed daily dopamine agonist treatment improves hypothalamic and neuroendocrine pathologies associated with MS and such neuroendocrine events are coupled to a transformation of liver metabolism potentiating a reduction of elevated lipogenic and gluconeogenic capacity. This liver effect may be driven in part by concurrent reductions in hyperinsulinemia and sympathetic tone as well as by reductions in intra-hepatic inflammation.

12 February 2016 in Expert Review of Endocrinology & Metabolism
Verified
Journal Article
Closed access
PRPhilip Raskin
Philip Raskin
ACAnthony H. Cincotta
Anthony H. Cincotta
An extended series of studies indicate that endogenous phase shifts in circadian neuronal input signaling to the biological clock system centered within the hypothalamic suprachiasmatic nucleus (SC...

12 April 2017 in Postgraduate Medicine
Verified
Journal Article
Open access
BCBindu Chamarthi
Bindu Chamarthi
ACAnthony H. Cincotta
Anthony H. Cincotta
Objective: The concurrent use of an insulin sensitizer in type 2 diabetes mellitus (T2DM) patients with inadequate glycemic control on basal-bolus insulin may help improve glycemic control while limiting further insulin requirement. Bromocriptine-QR (B-QR), a quick release, sympatholytic, dopamine D2 receptor agonist therapy for T2DM, is a postprandial insulin sensitizer. This study evaluated the effect of B-QR on dysglycemia in T2DM subjects with suboptimal glycemic control on basal-bolus insulin plus metformin. Methods: The effect of once-daily morning administration of B-QR on dysglycemia was evaluated in 60 T2DM subjects derived from the Cycloset Safety Trial, with HbA1c >7% on basal-bolus insulin plus metformin at baseline, randomized to B-QR (N = 44) versus placebo (N = 16) and completed 12 weeks of study drug treatment. The analyses also included a subset of subjects on high-dose insulin (total daily insulin dose (TDID) ≥70 units; N = 36: 27 B-QR; 9 placebo). Results: Subjects were well matched at baseline. After 12 weeks of B-QR treatment, mean % HbA1c decreased by -0.73% relative to baseline (p < 0.001) and by -1.13 relative to placebo (p < 0.001). In the high-dose insulin subset, B-QR therapy resulted in % HbA1c reductions of -0.95 and -1.49 relative to baseline (p < 0.001) and placebo (p = 0.001) respectively. Secondary analyses of treatment effect at 24 and 52 weeks demonstrated similar influences of B-QR on HbA1c. The fasting plasma glucose (FPG) and TDID changes within each treatment group were not significant. More subjects achieved HbA1c ≤7 at 12 weeks with B-QR relative to placebo (36.4% B-QR vs 0% placebo, Fisher’s exact 2-sided p = 0.003 in the entire cohort and 37% vs 0%, 2-sided p = 0.039 in the high-dose insulin subset). Conclusion: B-QR therapy improves glycemic control in T2DM subjects whose glycemia is poorly controlled on metformin plus basal-bolus insulin, including individuals on high-dose basal-bolus insulin. This glycemic impact occurred without significant change in FPG, suggesting a postprandial glucose lowering mechanism of action. Cycloset Safety Trial registration: ClinicalTrials.gov Identifier: NCT00377676

10 December 2017 in Journal of Neuroendocrinology
Verified
Journal Article
Open access
PDF file
SLS. Luo
S. Luo
YZY. Zhang
Y. Zhang
MEM. Ezrokhi
M. Ezrokhi
YLY. Li
Y. Li
TTT.‐H. Tsai
T.‐H. Tsai
ACAnthony H. Cincotta
Anthony H. Cincotta
Among vertebrate species of the major vertebrate classes in the wild, a seasonal rhythm of whole body fuel metabolism, oscillating from a lean to obese condition, is a common biological phenomenon. This annual cycle is driven in part by annual changes in the circadian dopaminergic signalling at the suprachiasmatic nuclei (SCN), with diminution of circadian peak dopaminergic activity at the SCN facilitating development of the seasonal obese insulin‐resistant condition. The present study investigated whether such an ancient circadian dopamine‐SCN activity system for expression of the seasonal obese, insulin‐resistant phenotype may be operative in animals made obese amd insulin resistant by high‐fat feeding and, if so, whether reinstatement of the circadian dopaminergic peak at the SCN would be sufficient to reverse the adverse metabolic impact of the high‐fat diet without any alteration of caloric intake. First, we identified the supramammillary nucleus as a novel site providing the majority of dopaminergic neuronal input to the SCN. We further identified dopamine D2 receptors within the peri‐SCN region as being functional in mediating SCN responsiveness to local dopamine. In lean, insulin‐sensitive rats, the peak in the circadian rhythm of dopamine release at the peri‐SCN coincided with the daily peak in SCN electrophysiological responsiveness to local dopamine administration. However, in rats made obese and insulin resistant by high‐fat diet (HFD) feeding, these coincident circadian peak activities were both markedly attenuated or abolished. Reinstatement of the circadian peak in dopamine level at the peri‐SCN by its appropriate circadian‐timed daily microinjection to this area (but not outside this circadian time‐interval) abrogated the obese, insulin‐resistant condition without altering the consumption of the HFD. These findings suggest that the circadian peak of dopaminergic activity at the peri‐SCN/SCN is a key modulator of metabolism and the responsiveness to adverse metabolic consequences of HFD consumption.